Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Isoniazid | Research

Estimating tuberculosis drug resistance amplification rates in high-burden settings

Authors: Malancha Karmakar, Romain Ragonnet, David B. Ascher, James M. Trauer, Justin T. Denholm

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Antimicrobial resistance develops following the accrual of mutations in the bacterial genome, and may variably impact organism fitness and hence, transmission risk. Classical representation of tuberculosis (TB) dynamics using a single or two strain (DS/MDR-TB) model typically does not capture elements of this important aspect of TB epidemiology. To understand and estimate the likelihood of resistance spreading in high drug-resistant TB incidence settings, we used epidemiological data to develop a mathematical model of Mycobacterium tuberculosis (Mtb) transmission.

Methods

A four-strain (drug-susceptible (DS), isoniazid mono-resistant (INH-R), rifampicin mono-resistant (RIF-R) and multidrug-resistant (MDR)) compartmental deterministic Mtb transmission model was developed to explore the progression from DS- to MDR-TB in The Philippines and Viet Nam. The models were calibrated using data from national tuberculosis prevalence (NTP) surveys and drug resistance surveys (DRS). An adaptive Metropolis algorithm was used to estimate the risks of drug resistance amplification among unsuccessfully treated individuals.

Results

The estimated proportion of INH-R amplification among failing treatments was 0.84 (95% CI 0.79–0.89) for The Philippines and 0.77 (95% CI 0.71–0.84) for Viet Nam. The proportion of RIF-R amplification among failing treatments was 0.05 (95% CI 0.04–0.07) for The Philippines and 0.011 (95% CI 0.010–0.012) for Viet Nam.

Conclusion

The risk of resistance amplification due to treatment failure for INH was dramatically higher than RIF. We observed RIF-R strains were more likely to be transmitted than acquired through amplification, while both mechanisms of acquisition were important contributors in the case of INH-R. These findings highlight the complexity of drug resistance dynamics in high-incidence settings, and emphasize the importance of prioritizing testing algorithms which allow for early detection of INH-R.
Appendix
Available only for authorised users
Literature
2.
go back to reference WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019.
3.
go back to reference Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis. 2017;17(1):36.PubMedPubMedCentralCrossRef Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis. 2017;17(1):36.PubMedPubMedCentralCrossRef
4.
5.
6.
go back to reference Fors J, Strydom N, Fox WS, Keizer RJ, Savic RM. Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis. PLoS Comput Biol. 2020;16(8):e1008107.PubMedPubMedCentralCrossRef Fors J, Strydom N, Fox WS, Keizer RJ, Savic RM. Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis. PLoS Comput Biol. 2020;16(8):e1008107.PubMedPubMedCentralCrossRef
7.
go back to reference Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035.PubMedCrossRef Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035.PubMedCrossRef
8.
9.
go back to reference Wikell A, Åberg H, Shedrawy J, Röhl I, Jonsson J, Berggren I, et al. Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study. BMC Public Health. 2019;19(1):151.PubMedPubMedCentralCrossRef Wikell A, Åberg H, Shedrawy J, Röhl I, Jonsson J, Berggren I, et al. Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study. BMC Public Health. 2019;19(1):151.PubMedPubMedCentralCrossRef
10.
go back to reference Naidoo P, van Niekerk M, du Toit E, Beyers N, Leon N. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients’ experiences in the era of rapid molecular diagnostic tests. BMC Health Serv Res. 2015;15:488.PubMedPubMedCentralCrossRef Naidoo P, van Niekerk M, du Toit E, Beyers N, Leon N. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients’ experiences in the era of rapid molecular diagnostic tests. BMC Health Serv Res. 2015;15:488.PubMedPubMedCentralCrossRef
11.
go back to reference Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.PubMedPubMedCentralCrossRef Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.PubMedPubMedCentralCrossRef
12.
go back to reference Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, et al. The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis. Clin Infect Dis. 2015;61(Suppl 3):S147–54.PubMedCentralCrossRef Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, et al. The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis. Clin Infect Dis. 2015;61(Suppl 3):S147–54.PubMedCentralCrossRef
13.
go back to reference Karmakar M, Globan M, Fyfe JAM, Stinear TP, Johnson PDR, Holmes NE, et al. Analysis of a novel pncA mutation for susceptibility to pyrazinamide therapy. Am J Respir Crit Care Med. 2018;198(4):541–4.PubMedPubMedCentralCrossRef Karmakar M, Globan M, Fyfe JAM, Stinear TP, Johnson PDR, Holmes NE, et al. Analysis of a novel pncA mutation for susceptibility to pyrazinamide therapy. Am J Respir Crit Care Med. 2018;198(4):541–4.PubMedPubMedCentralCrossRef
14.
go back to reference Karmakar M, Rodrigues CHM, Horan K, Denholm JT, Ascher DB. Structure guided prediction of Pyrazinamide resistance mutations in pncA. Sci Rep. 2020;10(1):1875.PubMedPubMedCentralCrossRef Karmakar M, Rodrigues CHM, Horan K, Denholm JT, Ascher DB. Structure guided prediction of Pyrazinamide resistance mutations in pncA. Sci Rep. 2020;10(1):1875.PubMedPubMedCentralCrossRef
15.
go back to reference Karmakar M, Rodrigues CHM, Holt KE, Dunstan SJ, Denholm J, Ascher DB. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS ONE. 2019;14(5):e0217169.PubMedPubMedCentralCrossRef Karmakar M, Rodrigues CHM, Holt KE, Dunstan SJ, Denholm J, Ascher DB. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS ONE. 2019;14(5):e0217169.PubMedPubMedCentralCrossRef
16.
go back to reference Trauer JM, Denholm JT, McBryde ES. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-pacific. J Theor Biol. 2014;358:74–84.PubMedCrossRef Trauer JM, Denholm JT, McBryde ES. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-pacific. J Theor Biol. 2014;358:74–84.PubMedCrossRef
17.
go back to reference Ragonnet R, Trauer JM, Scott N, Meehan MT, Denholm JT, McBryde ES. Optimally capturing latency dynamics in models of tuberculosis transmission. Epidemics. 2017;21:39–47.PubMedCrossRef Ragonnet R, Trauer JM, Scott N, Meehan MT, Denholm JT, McBryde ES. Optimally capturing latency dynamics in models of tuberculosis transmission. Epidemics. 2017;21:39–47.PubMedCrossRef
18.
go back to reference Ragonnet R, Flegg JA, Brilleman SL, Tiemersma EW, Melsew YA, McBryde ES, et al. Revisiting the natural history of pulmonary tuberculosis: a Bayesian estimation of natural recovery and mortality rates. Clin Infect Dis 2020. Ragonnet R, Flegg JA, Brilleman SL, Tiemersma EW, Melsew YA, McBryde ES, et al. Revisiting the natural history of pulmonary tuberculosis: a Bayesian estimation of natural recovery and mortality rates. Clin Infect Dis 2020.
19.
go back to reference Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES, et al. Risk of active tuberculosis in the five years following infection … 15%? Chest. 2016;149(2):516–25.PubMedCrossRef Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES, et al. Risk of active tuberculosis in the five years following infection … 15%? Chest. 2016;149(2):516–25.PubMedCrossRef
20.
go back to reference Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3(1):13–21.PubMedCrossRef Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3(1):13–21.PubMedCrossRef
21.
go back to reference Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tubercul Lung Dis. 2009;13(12):1456–66. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tubercul Lung Dis. 2009;13(12):1456–66.
22.
go back to reference Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect. 2009;15(Suppl 1):66–8.PubMedCrossRef Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect. 2009;15(Suppl 1):66–8.PubMedCrossRef
23.
go back to reference Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Med. 2004;10(10):1117–21.PubMedCrossRef Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Med. 2004;10(10):1117–21.PubMedCrossRef
24.
go back to reference Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88(4):273–80.PubMedPubMedCentralCrossRef Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88(4):273–80.PubMedPubMedCentralCrossRef
25.
go back to reference Nguyen HV, Tiemersma EW, Nguyen HB, Cobelens FGJ, Finlay A, Glaziou P, et al. The second national tuberculosis prevalence survey in Vietnam. PLoS ONE. 2020;15(4):e0232142.PubMedPubMedCentralCrossRef Nguyen HV, Tiemersma EW, Nguyen HB, Cobelens FGJ, Finlay A, Glaziou P, et al. The second national tuberculosis prevalence survey in Vietnam. PLoS ONE. 2020;15(4):e0232142.PubMedPubMedCentralCrossRef
26.
go back to reference Tupasi TE, Radhakrishna S, Chua JA, Mangubat NV, Guilatco R, Galipot M, et al. Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS. Int J tuberc Lung Dis. 2009;13(10):1224–30.PubMed Tupasi TE, Radhakrishna S, Chua JA, Mangubat NV, Guilatco R, Galipot M, et al. Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS. Int J tuberc Lung Dis. 2009;13(10):1224–30.PubMed
28.
go back to reference Nhung NV, Hoa NB, Sy DN, Hennig CM, Dean AS. The fourth national anti-tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015;19(6):670–5.PubMedCrossRef Nhung NV, Hoa NB, Sy DN, Hennig CM, Dean AS. The fourth national anti-tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015;19(6):670–5.PubMedCrossRef
29.
go back to reference Nationwide drug resistance survey of tuberculosis in the Philippines. Int J Tuberc Lung Dis 2009;13(4):500–7. Nationwide drug resistance survey of tuberculosis in the Philippines. Int J Tuberc Lung Dis 2009;13(4):500–7.
30.
go back to reference Haario H, Saksman E, Tamminen J. An adaptive metropolis algorithm. Bernoulli. 2001;7(2):223–42.CrossRef Haario H, Saksman E, Tamminen J. An adaptive metropolis algorithm. Bernoulli. 2001;7(2):223–42.CrossRef
31.
32.
go back to reference Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA. 1993;270(1):65–8.PubMedCrossRef Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA. 1993;270(1):65–8.PubMedCrossRef
33.
go back to reference Eidus L, Jessamine AG, Hershfield ES, Helbecque DM. A national study to determine the prevalence of drug resistance in newly discovered previously untreated tuberculosis patients as well as in retreatment cases. Can J Public Health = Revue canadienne de sante publique. 1978;69(2):146–53.PubMed Eidus L, Jessamine AG, Hershfield ES, Helbecque DM. A national study to determine the prevalence of drug resistance in newly discovered previously untreated tuberculosis patients as well as in retreatment cases. Can J Public Health = Revue canadienne de sante publique. 1978;69(2):146–53.PubMed
34.
go back to reference Chiang C-Y, Trébucq A. Tuberculosis re-treatment after exclusion of rifampicin resistance. Eur Respir J. 2018;51(2):1702282.PubMedCrossRef Chiang C-Y, Trébucq A. Tuberculosis re-treatment after exclusion of rifampicin resistance. Eur Respir J. 2018;51(2):1702282.PubMedCrossRef
35.
go back to reference Quy HT, Lan NT, Lönnroth K, Buu TN, Dieu TT, Hai LT. Public-private mix for improved TB control in Ho Chi Minh City, Vietnam: an assessment of its impact on case detection. Int J Tuberc Lung Dis. 2003;7(5):464–71.PubMed Quy HT, Lan NT, Lönnroth K, Buu TN, Dieu TT, Hai LT. Public-private mix for improved TB control in Ho Chi Minh City, Vietnam: an assessment of its impact on case detection. Int J Tuberc Lung Dis. 2003;7(5):464–71.PubMed
36.
go back to reference Tupasi TE, Radhakrishna S, Co VM, Villa ML, Quelapio MI, Mangubat NV, et al. Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control. Int J Tuberc Lung Dis. 2000;4(12):1126–32.PubMed Tupasi TE, Radhakrishna S, Co VM, Villa ML, Quelapio MI, Mangubat NV, et al. Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control. Int J Tuberc Lung Dis. 2000;4(12):1126–32.PubMed
37.
go back to reference Lönnroth K, Thuong LM, Lambregts K, Quy HT, Diwan VK. Private tuberculosis care provision associated with poor treatment outcome: comparative study of a semi-private lung clinic and the NTP in two urban districts in Ho Chi Minh City, Vietnam. National Tuberculosis Programme. Int J Tuberc Lung Dis. 2003;7(2):165–71.PubMed Lönnroth K, Thuong LM, Lambregts K, Quy HT, Diwan VK. Private tuberculosis care provision associated with poor treatment outcome: comparative study of a semi-private lung clinic and the NTP in two urban districts in Ho Chi Minh City, Vietnam. National Tuberculosis Programme. Int J Tuberc Lung Dis. 2003;7(2):165–71.PubMed
38.
go back to reference Buu TN, Lönnroth K, Quy HT. Initial defaulting in the National Tuberculosis Programme in Ho Chi Minh City, Vietnam: a survey of extent, reasons and alternative actions taken following default. Int J Tuberc Lung Dis. 2003;7(8):735–41.PubMed Buu TN, Lönnroth K, Quy HT. Initial defaulting in the National Tuberculosis Programme in Ho Chi Minh City, Vietnam: a survey of extent, reasons and alternative actions taken following default. Int J Tuberc Lung Dis. 2003;7(8):735–41.PubMed
39.
go back to reference Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–53.PubMedPubMedCentralCrossRef Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–53.PubMedPubMedCentralCrossRef
40.
go back to reference Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis. 2008;47(9):1126–34.PubMedCrossRef Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis. 2008;47(9):1126–34.PubMedCrossRef
41.
go back to reference Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015;3(12):963–72.PubMedPubMedCentralCrossRef Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015;3(12):963–72.PubMedPubMedCentralCrossRef
42.
go back to reference Tsara V, Serasli E, Christaki P. Problems in diagnosis and treatment of tuberculosis infection. Hippokratia. 2009;13(1):20–2.PubMedPubMedCentral Tsara V, Serasli E, Christaki P. Problems in diagnosis and treatment of tuberculosis infection. Hippokratia. 2009;13(1):20–2.PubMedPubMedCentral
43.
go back to reference Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001;104(6):901–12.PubMedCrossRef Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001;104(6):901–12.PubMedCrossRef
44.
go back to reference Dlamini MT, Lessells R, Iketleng T, de Oliveira T. Whole genome sequencing for drug-resistant tuberculosis management in South Africa: what gaps would this address and what are the challenges to implementation? J Clin Tuberc Other Mycobact Dis. 2019;16:100115.PubMedPubMedCentralCrossRef Dlamini MT, Lessells R, Iketleng T, de Oliveira T. Whole genome sequencing for drug-resistant tuberculosis management in South Africa: what gaps would this address and what are the challenges to implementation? J Clin Tuberc Other Mycobact Dis. 2019;16:100115.PubMedPubMedCentralCrossRef
45.
go back to reference Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, et al. Multicenter noninferiority evaluation of hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol. 2016;54(6):1624–30.PubMedPubMedCentralCrossRef Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, et al. Multicenter noninferiority evaluation of hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol. 2016;54(6):1624–30.PubMedPubMedCentralCrossRef
46.
go back to reference de Vos M, Derendinger B, Dolby T, Simpson J, van Helden PD, Rice JE, et al. Diagnostic accuracy and utility of FluoroType MTBDR, a new molecular assay for multidrug-resistant tuberculosis. J Clin Microbiol. 2018;56(9):1. de Vos M, Derendinger B, Dolby T, Simpson J, van Helden PD, Rice JE, et al. Diagnostic accuracy and utility of FluoroType MTBDR, a new molecular assay for multidrug-resistant tuberculosis. J Clin Microbiol. 2018;56(9):1.
47.
go back to reference Hofmann-Thiel S, Plesnik S, Mihalic M, Heiß-Neumann M, Avsar K, Beutler M, et al. Clinical evaluation of BD MAX MDR-TB assay for direct detection of Mycobacterium tuberculosis complex and resistance markers. J Mol Diagn. 2020;22(10):1280–6.PubMedCrossRef Hofmann-Thiel S, Plesnik S, Mihalic M, Heiß-Neumann M, Avsar K, Beutler M, et al. Clinical evaluation of BD MAX MDR-TB assay for direct detection of Mycobacterium tuberculosis complex and resistance markers. J Mol Diagn. 2020;22(10):1280–6.PubMedCrossRef
48.
go back to reference Nadarajan D, Hillemann D, Kamara R, Foray L, Conteh OS, Merker M, et al. Evaluation of the Roche cobas MTB and MTB-RIF/INH assays in samples from Germany and Sierra Leone. J Clin Microbiol. 2021;59(5):e02983-e3020.PubMedPubMedCentralCrossRef Nadarajan D, Hillemann D, Kamara R, Foray L, Conteh OS, Merker M, et al. Evaluation of the Roche cobas MTB and MTB-RIF/INH assays in samples from Germany and Sierra Leone. J Clin Microbiol. 2021;59(5):e02983-e3020.PubMedPubMedCentralCrossRef
49.
go back to reference Talbot EA, Pai M. Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. Int J Tuberc Lung Dis. 2019;23(7):774–82.PubMedCrossRef Talbot EA, Pai M. Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. Int J Tuberc Lung Dis. 2019;23(7):774–82.PubMedCrossRef
50.
go back to reference Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265–75.PubMedCrossRef Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265–75.PubMedCrossRef
51.
go back to reference Dunstan SJ, Williamson DA, Denholm JT. Understanding the global tuberculosis epidemic: moving towards routine whole-genome sequencing. Int J Tuberc Lung Dis. 2019;23(12):1241–2.PubMedCrossRef Dunstan SJ, Williamson DA, Denholm JT. Understanding the global tuberculosis epidemic: moving towards routine whole-genome sequencing. Int J Tuberc Lung Dis. 2019;23(12):1241–2.PubMedCrossRef
52.
go back to reference Mahomed S, Naidoo K, Dookie N, Padayatchi N. Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: challenges and implications. Tuberculosis (Edinb). 2017;107:137–43.CrossRef Mahomed S, Naidoo K, Dookie N, Padayatchi N. Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: challenges and implications. Tuberculosis (Edinb). 2017;107:137–43.CrossRef
53.
go back to reference Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, et al. Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings with a high burden of tuberculosis. Tuberculosis (Edinb). 2014;94(4):434–40.CrossRef Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, et al. Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings with a high burden of tuberculosis. Tuberculosis (Edinb). 2014;94(4):434–40.CrossRef
Metadata
Title
Estimating tuberculosis drug resistance amplification rates in high-burden settings
Authors
Malancha Karmakar
Romain Ragonnet
David B. Ascher
James M. Trauer
Justin T. Denholm
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07067-1

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.